| 商品名称 | Cresemba |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Aspergillosis |
| 通用名/非专利名称 | isavuconazole |
| 活性成分 | isavuconazole |
| 产品号 | EMEA/H/C/002734 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | J02AC05 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | Yes |
| 上市许可日期 | 2015/10/15 |
| 上市许可开发者/申请人/持有人 | Basilea Pharmaceutica Deutschland GmbH |
| 人用药物治疗学分组 | Antimycotics for systemic use;Triazole derivatives |
| 兽用药物治疗学分组 | |
| 审评意见日期 | 2005/07/23 |
| 欧盟委员会决定日期 | 2025/07/17 |
| 修订号 | 21 |
| 治疗适应症 | Powder for concentrate for solution for infusion: Cresemba is indicated in patients from 1 year of age and older for the treatment of invasive aspergillosis mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1) Consideration should be given to official guidance on the appropriate use of antifungal agents. Hard capsules: Cresemba hard capsules are indicated in adults and in paediatric patients from 6 years of age for the treatment of invasive aspergillosis mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1) Consideration should be given to official guidance on the appropriate use of antifungal agents. Cresemba 40 mg hard capsules are intended to be used for paediatric patients. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2017/08/24 |
| 最后更新日期 | 2025/07/24 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/cresemba-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba |